ALGN

Align Technology operates with a distinctive capital structure profile in the medical device sector, maintaining a debt-to-equity ratio of 0.0 while generating an ROE of 10.7%. Trading at $158.78 with a market capitalization of $11.3 billion, the company demonstrates characteristic volatility through its beta of 1.67, reflecting sensitivity to broader market movements in the discretionary healthcare segment.

The fundamental screener highlights several operational strengths in the current profile:

• Premium margin structure: Gross margin of 68.58% positions the company well above typical manufacturing benchmarks, though the 13.59% operating margin indicates substantial investment in research and commercial infrastructure supporting the clear aligner category.
• Conservative balance sheet: The absence of financial leverage combined with a current ratio of 1.36 provides operational flexibility during market volatility, particularly relevant given the 24% decline from the 52-week high of $208.31.
• Moderate profitability metrics: Net margin of 10.5% and ROA of 6.88% demonstrate reasonable efficiency, while the P/E ratio of 26.2 reflects market expectations for growth beyond the current 2.89% revenue expansion rate.

Risk parameters include the deceleration in top-line momentum, with revenue growth of 2.89% YoY signaling potential market maturation or competitive pressure in core orthodontic channels. The P/S multiple of 2.75 appears elevated relative to the single-digit growth profile, suggesting valuation compression risk if operating leverage fails to materialize.

Relative to peers including MDLN and SOLV, the research perspective indicates Align's premium valuation multiples require sustained margin expansion and accelerating procedure volumes to justify current price levels within systematic screening frameworks.